Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Reck, M. [1 ]
Frickhofen, N. [2 ]
Gatzemeier, U. [1 ]
Fuhr, H. G. [2 ]
Lanzalone, S. [3 ]
Wang, E. [4 ]
Chao, R. [4 ]
Felip, E. [5 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] Dr Horst Schmidt Klin, Wiesbaden, Germany
[3] Pfizer Italia, Milan, Italy
[4] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
[5] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71435-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results
    Steward, WP
    Dunlop, DJ
    Dabouis, G
    Lacroix, H
    Talbot, D
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 43 - 47
  • [22] Phase II study of Gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer
    Mohedano, N
    Medina, MB
    Sanchez, P
    Jaen, A
    Gonzalez, E
    Porras, I
    Fernandez, M
    Lozano, A
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [23] Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    D. Ross Camidge
    Normand Blais
    Derek J. Jonker
    Denis Soulières
    Robert C. Doebele
    Ana Ruiz-Garcia
    Aron Thall
    Ke Zhang
    Scott A. Laurie
    Richard C. Chao
    Laura Q. Chow
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 307 - 319
  • [24] Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    Camidge, D. Ross
    Blais, Normand
    Jonker, Derek J.
    Soulieres, Denis
    Doebele, Robert C.
    Ruiz-Garcia, Ana
    Thall, Aron
    Zhang, Ke
    Laurie, Scott A.
    Chao, Richard C.
    Chow, Laura Q.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 307 - 319
  • [25] Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results of an ongoing phase I/II study
    Steward, WP
    Dunlop, DJ
    Cameron, C
    Talbot, DC
    Kleisbauer, JP
    Thomas, P
    Guerin, JC
    Perol, M
    Sanson, C
    Dabouis, G
    Lacroix, H
    ANTI-CANCER DRUGS, 1995, 6 : 33 - 37
  • [26] Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer
    Shepherd, FA
    Latreille, J
    Paul, K
    Eisenhauer, E
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 84 - 90
  • [27] Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study
    Spira, Alexander I.
    Cho, Byoung Chul
    Kim, Tae Min
    Kim, Sang-We
    Xia, Bing
    Artis, Eunice
    Dobbs, Jessica
    Baudelet, Christine
    Baig, Mahadi
    Sendur, Mehmet Ali Nahit
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] PHASE I DOSE-ESCALATION STUDY OF VORINOSTAT COMBINED WITH GEMCITABINE AND PLATINUM AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER
    Descourt, R.
    Zalcman, G.
    Moro-Sibilot, D.
    Tredaniel, J.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Reiser, D.
    Roben, E.
    Rizvi, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [29] Divided doses of cisplatin in combination with gemcitabine for patients with advanced non-small cell lung cancer (NSCLC).
    Demirkazik, A
    Yalcin, B
    Akbulut, H
    Buyukcelik, A
    Cay, F
    Utkan, G
    Icli, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [30] Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer
    Esteban, E
    Fra, J
    Sala, M
    Carrasco, J
    Corral, N
    Vieitez, JM
    Estrada, E
    Palacio, I
    Buesa, JM
    Lacave, AJ
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 317 - 326
12345